Developer docs
API playgroundTry for free, no card

Search company profiles

Numinus Wellness

Full company profile

uuid000b8y6

Namestring
Numinus Wellness
Legal namestring
Numinus Wellness Inc.
Company typeenum
Public
Founded yearint
2020
Descriptiontext

Numinus Wellness Inc. is a Canadian mental health company advancing psychedelic-assisted therapy through a vertically integrated platform spanning three business lines: clinical services delivered through a Canadian clinic network (Vancouver, Montreal, Toronto), accredited practitioner training, and clinical trial site operations via Cedar Clinical Research. The company is built around a Health Canada-licensed laboratory, Numinus Bioscience, which holds licenses for psilocybin, DMT, MDMA, mescaline, psilocin, LSD, and ketamine for research and production — a regulatory footprint that positioned Numinus as the first publicly traded company in Canada approved to extract and research psilocybin. Service offerings include ketamine-assisted therapy (including Spravato), psilocybin-assisted therapy for treatment-resistant depression, PTSD, and substance use disorders, MDMA-assisted therapy through the MAPS compassionate access trial, and adjunctive modalities such as TMS. The Numinus Care Model — a seven-principle framework covering trauma-informed care, cultural safety, harm reduction, mindfulness, and embodiment — is the codified methodology applied across clinical and training delivery.

On the commercial side, Numinus monetizes through three primary streams: clinical services revenue from patient treatment, professional fees from the board-accredited training platform (Fundamentals of PAT, Applied PAT, Molecular Foundations, Embodied Inquiry, and Psychedelic Harm Reduction & Integration), and laboratory/research services revenue from psychedelic compound production and clinical trial site operations. The practitioner training platform has trained over 2,500 practitioners to date and feeds a Numinus Alumni Network that generates referral flows and continued engagement. Distribution is direct-to-consumer for clinics and self-serve online for training, with no channel partner or reseller model. The company is currently under a cease trade order from the British Columbia Securities Commission, was delisted from the TSX effective April 22, 2026, and has filed an application to list on the Canadian Securities Exchange. Following the 2024 divestiture of US operations (five Utah clinics sold to Stella for US$3.53 million), the company has narrowed its footprint to Canadian clinical and research operations along with its global online training platform, and is pursuing a strategic rebrand to Numinus Intelligence through the MedBright AI acquisition.

Short descriptiontext

Numinus Wellness is a Canadian psychedelic-assisted therapy company operating a vertically integrated platform of clinical services, practitioner training, and clinical trial site operations, supported by a Health Canada-licensed laboratory (Numinus Bioscience) and a training community of over 2,500 practitioners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersVancouver, Canada
HQ citystring
Vancouver
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
psychedelic-assisted therapy, clinical trials, mental health services, practitioner training, psychedelic research
Industry2 codes
PRIMARYHLALAEAA
General Mental Health Therapy Platforms (Talk Therapy)
Healthcare & Life Sciences/Telehealth Platforms/Behavioral & Mental Health Teletherapy Platforms
SECONDARYHSADAJAH
Meditation Apps, Digital Courses & Online Communities
NAICS code2 codes
  • Outpatient Mental Health and Substance Abuse Centers621420
  • Offices of Mental Health Practitioners (except Physicians)621330
SIC code2 codes
  • Services-Health Services8000
  • Services-Misc Health & Allied Services, Nec8090
Product category
Mental Health Services
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Clinical Services Revenue
TypeProfessional Services
Description

Revenue generated from psychedelic-assisted therapy clinical services delivered through the company's clinic network in Canada (Vancouver, Montreal, Toronto) and through Cedar Clinical Research's trial site operations.

numinusnetwork.com
2Practitioner Training Programs
TypeProfessional Services
Description

Board-accredited certification pathways and stand-alone courses in psychedelic-assisted therapy, including Fundamentals of PAT, Applied PAT, Molecular Foundations, and Harm Reduction & Integration. Training programs serve both licensed mental health professionals and non-licensed practitioners.

numinusnetwork.com
3Laboratory & Research Services
TypeProfessional Services
Description

Health Canada licensed laboratory services through Numinus Bioscience, including psychedelic compound production, extraction (including psilocybin, DMT, MDMA, mescaline, psilocin, LSD, ketamine), and manufacturing of finished products for research supply.

numinusnetwork.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Fundamentals of Psychedelic-Assisted Therapy — approximately 50 hours over 8 weeks with 2.5-hour pre-work modules and 3-hour live interactive sessions plus small group learning
ModelSubscriptionBilling cadenceMonthly
Notes

The Fundamentals course covers preparation, administration, and integration through the Numinus Care Model and includes an experiential cacao ceremony. Specific pricing is not publicly listed on the website.

numinusnetwork.com
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 of 4 records shown
1Numinus Health
Description

Clinic operations and patient care division providing psychedelic-assisted therapies

numinusnetwork.com
+3 more records
Core offering1 text field

Numinus Wellness operates an integrated mental health company delivering psychedelic-assisted therapy clinical services through owned clinics in Canada (Vancouver, Montreal, Toronto), board-accredited practitioner training programs for psychedelic therapy certification, and clinical trial site operations (Cedar Clinical Research) supporting psychedelic medicine research. Supporting infrastructure includes Numinus Bioscience, a Health Canada licensed laboratory for psychedelic compound production and extraction covering psilocybin, DMT, MDMA, mescaline, psilocin, LSD, and ketamine.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Revenue increased 160% year-over-year for Q3 2021 vs. Q3 2020 (Q3 2021: $562,076 vs. Q3 2020: $216,244)
+3 more records
Product overview1 text field

Numinus Wellness operates as an integrated mental health company offering a platform of clinical services, provider training, and clinical research. The core offerings include Provider Training (accredited psychedelic-assisted therapy certification programs), Clinical Trials (through Cedar Clinical Research), and direct patient treatment services (ketamine, psilocybin, and MDMA-assisted therapy). Supporting infrastructure includes Numinus Bioscience (research laboratory), the Numinus Care Model (trauma-informed care framework), and the Numinus Alumni Network (graduate support community). The company also operates clinics across Canada and acquired the Neurology Centre of Toronto to expand into psychedelic neurology services.

Product and service7 records
1Provider Training
CategoryProfessional Education / Certification
Description

Board-accredited Psychedelic-Assisted Therapy certification programs and stand-alone courses for licensed mental health professionals and non-licensed practitioners, covering ketamine, psilocybin, and MDMA-assisted therapy. Over 2,500 practitioners trained to date.

2Clinical Trials
CategoryClinical Research Services
Description

Clinical research site services through Cedar Clinical Research, conducting psychedelic-assisted therapy trials, compassionate access programs, and Phase 1 studies for pharmaceutical and research clients.

3Ketamine-Assisted Therapy
CategoryClinical Therapy Services
Description

Clinical treatment using ketamine for depression, anxiety, PTSD, and other mental health conditions, including Spravato (esketamine) treatments, delivered in owned Canadian clinics.

4Psilocybin-Assisted Therapy
CategoryClinical Therapy Services
Description

Treatment using psilocybin for treatment-resistant depression, PTSD, anxiety, and substance use disorders through clinical trials and Health Canada Special Access Program.

5MDMA-Assisted Therapy
CategoryClinical Therapy Services
Description

Treatment using MDMA for PTSD delivered through MAPS-sponsored clinical trials and compassionate access programs.

6Numinus Bioscience
CategoryLaboratory Research and Manufacturing
Description

Health Canada licensed laboratory conducting psychedelic research, extraction, and production including psilocybin, DMT, MDMA, mescaline, psilocin, LSD, and ketamine for clinical trials and research supply.

7Transcranial Magnetic Stimulation (TMS)
CategoryClinical Therapy Services
Description

Non-invasive brain stimulation therapy offered at Neurology Centre of Toronto by Numinus alongside psychedelic-assisted therapies.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-11-15
Description

As part of the US$3.53 million sale of five Utah clinics, Numinus entered into a data partnership with Stella for data sharing to develop clinic management solutions. Stella enhances operational efficiency across its clinic network through this arrangement.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-20
Description

Numinus announced strategic acquisition of MedBright AI, with plans to rebrand as Numinus Intelligence to leverage AI in mental health clinics across the U.S. The transaction involves issuing approximately 204.7 million Numinus shares. The acquisition aims to enhance mental health treatment offerings through AI-enabled solutions and generate revenue and profitability.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-07-12
Description

Health Canada approved the compassionate access trial of MDMA-assisted therapy for PTSD and concurrent disorders in collaboration with MAPS. This partnership enables real-world data collection on a regulated model for MDMA-assisted therapy, leveraging Numinus' clinical trial site infrastructure.

4Dr. Gabor Maté (Clinical Advisory Council)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-05-26
Description

Dr. Gabor Maté, a recognized physician and bestselling author, joined Numinus as a member of the Clinical Advisory Council. He collaborates with the Numinus team in an advisory capacity and facilitates connections within the mental health community.

numinusnetwork.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Health Canada has granted Numinus Bioscience licenses enabling research, extraction, and production of controlled substances including psilocybin, DMT, MDMA, mescaline, psilocin, LSD, and ketamine. Through the Special Access Program (SAP), physicians can request access to psilocybin and MDMA for patients with treatment-resistant conditions.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Numinus Wellness

Mental Health Servicesnuminusnetwork.com

Numinus Wellness is a Canadian psychedelic-assisted therapy company operating a vertically integrated platform of clinical services, practitioner training, and clinical trial site operations, supported by a Health Canada-licensed laboratory (Numinus Bioscience) and a training community of over 2,500 practitioners.

What Numinus Wellness does

Numinus Wellness Inc. is a Canadian mental health company advancing psychedelic-assisted therapy through a vertically integrated platform spanning three business lines: clinical services delivered through a Canadian clinic network (Vancouver, Montreal, Toronto), accredited practitioner training, and clinical trial site operations via Cedar Clinical Research. The company is built around a Health Canada-licensed laboratory, Numinus Bioscience, which holds licenses for psilocybin, DMT, MDMA, mescaline, psilocin, LSD, and ketamine for research and production — a regulatory footprint that positioned Numinus as the first publicly traded company in Canada approved to extract and research psilocybin. Service offerings include ketamine-assisted therapy (including Spravato), psilocybin-assisted therapy for treatment-resistant depression, PTSD, and substance use disorders, MDMA-assisted therapy through the MAPS compassionate access trial, and adjunctive modalities such as TMS. The Numinus Care Model — a seven-principle framework covering trauma-informed care, cultural safety, harm reduction, mindfulness, and embodiment — is the codified methodology applied across clinical and training delivery.

On the commercial side, Numinus monetizes through three primary streams: clinical services revenue from patient treatment, professional fees from the board-accredited training platform (Fundamentals of PAT, Applied PAT, Molecular Foundations, Embodied Inquiry, and Psychedelic Harm Reduction & Integration), and laboratory/research services revenue from psychedelic compound production and clinical trial site operations. The practitioner training platform has trained over 2,500 practitioners to date and feeds a Numinus Alumni Network that generates referral flows and continued engagement. Distribution is direct-to-consumer for clinics and self-serve online for training, with no channel partner or reseller model. The company is currently under a cease trade order from the British Columbia Securities Commission, was delisted from the TSX effective April 22, 2026, and has filed an application to list on the Canadian Securities Exchange. Following the 2024 divestiture of US operations (five Utah clinics sold to Stella for US$3.53 million), the company has narrowed its footprint to Canadian clinical and research operations along with its global online training platform, and is pursuing a strategic rebrand to Numinus Intelligence through the MedBright AI acquisition.

Numinus Wellness firmographics

Firmographics
Name
Numinus Wellness
Legal name
Numinus Wellness Inc.
Website
https://numinusnetwork.com
Company type
Public
Founded year
2020
Operating status
Operating
Headcount range
51–100 employees
Short description
Numinus Wellness is a Canadian psychedelic-assisted therapy company operating a vertically integrated platform of clinical services, practitioner training, and clinical trial site operations, supported by a Health Canada-licensed laboratory (Numinus Bioscience) and a training community of over 2,500 practitioners.
Ownership category
akta.pro rank

Numinus Wellness industry classification

Industry
Product category
Mental Health Services
NAICS
Outpatient Mental Health and Substance Abuse Centers (621420), Offices of Mental Health Practitioners (except Physicians) (621330)
SIC
Services-Health Services (8000), Services-Misc Health & Allied Services, Nec (8090)
akta.pro industry
PRIMARYHLALAEAA
General Mental Health Therapy Platforms (Talk Therapy)
Healthcare & Life Sciences/Telehealth Platforms/Behavioral & Mental Health Teletherapy Platforms
SECONDARYHSADAJAH
Meditation Apps, Digital Courses & Online Communities

Keywords

  • Psychedelic-assisted therapy
  • Clinical trials
  • Mental health services
  • Practitioner training
  • Psychedelic research

Where Numinus Wellness is headquartered

Location

Headquarters

HQ city
Vancouver
HQ country
Canada
HQ region
North America

Offices4 records

Markets served

Numinus Wellness business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Clinical Services Revenue: Revenue generated from psychedelic-assisted therapy clinical services delivered through the company's clinic network in Canada (Vancouver, Montreal, Toronto) and through Cedar Clinical Research's trial site operations.
  2. Practitioner Training Programs: Board-accredited certification pathways and stand-alone courses in psychedelic-assisted therapy, including Fundamentals of PAT, Applied PAT, Molecular Foundations, and Harm Reduction & Integration. Training programs serve both licensed mental health professionals and non-licensed practitioners.
  3. Laboratory & Research Services: Health Canada licensed laboratory services through Numinus Bioscience, including psychedelic compound production, extraction (including psilocybin, DMT, MDMA, mescaline, psilocin, LSD, ketamine), and manufacturing of finished products for research supply.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyFundamentals of Psychedelic-Assisted Therapy — approximately 50 hours over 8 weeks with 2.5-hour pre-work modules and 3-hour live interactive sessions plus small group learning

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Numinus Wellness product offering

Product offering

Core offering

Numinus Wellness operates an integrated mental health company delivering psychedelic-assisted therapy clinical services through owned clinics in Canada (Vancouver, Montreal, Toronto), board-accredited practitioner training programs for psychedelic therapy certification, and clinical trial site operations (Cedar Clinical Research) supporting psychedelic medicine research. Supporting infrastructure includes Numinus Bioscience, a Health Canada licensed laboratory for psychedelic compound production and extraction covering psilocybin, DMT, MDMA, mescaline, psilocin, LSD, and ketamine.

Product overview

Numinus Wellness operates as an integrated mental health company offering a platform of clinical services, provider training, and clinical research. The core offerings include Provider Training (accredited psychedelic-assisted therapy certification programs), Clinical Trials (through Cedar Clinical Research), and direct patient treatment services (ketamine, psilocybin, and MDMA-assisted therapy). Supporting infrastructure includes Numinus Bioscience (research laboratory), the Numinus Care Model (trauma-informed care framework), and the Numinus Alumni Network (graduate support community). The company also operates clinics across Canada and acquired the Neurology Centre of Toronto to expand into psychedelic neurology services.

Differentiator

Problem solved

Functional benefit

Brands

  • Numinus Health: Clinic operations and patient care division providing psychedelic-assisted therapies
  • Numinus Bioscience
  • Numinus Training
  • Neurology Centre of Toronto by Numinus

Products and services

  • Provider Training Board-accredited Psychedelic-Assisted Therapy certification programs and stand-alone courses for licensed mental health professionals and non-licensed practitioners, covering ketamine, psilocybin, and MDMA-assisted therapy. Over 2,500 practitioners trained to date.
  • Clinical Trials Clinical research site services through Cedar Clinical Research, conducting psychedelic-assisted therapy trials, compassionate access programs, and Phase 1 studies for pharmaceutical and research clients.
  • Ketamine-Assisted Therapy Clinical treatment using ketamine for depression, anxiety, PTSD, and other mental health conditions, including Spravato (esketamine) treatments, delivered in owned Canadian clinics.
  • Psilocybin-Assisted Therapy Treatment using psilocybin for treatment-resistant depression, PTSD, anxiety, and substance use disorders through clinical trials and Health Canada Special Access Program.
  • MDMA-Assisted Therapy Treatment using MDMA for PTSD delivered through MAPS-sponsored clinical trials and compassionate access programs.
  • Numinus Bioscience Health Canada licensed laboratory conducting psychedelic research, extraction, and production including psilocybin, DMT, MDMA, mescaline, psilocin, LSD, and ketamine for clinical trials and research supply.
  • Transcranial Magnetic Stimulation (TMS) Non-invasive brain stimulation therapy offered at Neurology Centre of Toronto by Numinus alongside psychedelic-assisted therapies.

Quantifiable outcome

  • Revenue increased 160% year-over-year for Q3 2021 vs. Q3 2020 (Q3 2021: $562,076 vs. Q3 2020: $216,244)
  • +3 more outcomes

Companies that use Numinus Wellness

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Numinus Wellness technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Numinus Wellness partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor and core.

  • StellaminorStrategic or Co-development Partner · 15 November 2024As part of the US$3.53 million sale of five Utah clinics, Numinus entered into a data partnership with Stella for data sharing to develop clinic management solutions. Stella enhances operational efficiency across its clinic network through this arrangement.
  • MedBright AIcoreStrategic or Co-development Partner · 20 June 2024Numinus announced strategic acquisition of MedBright AI, with plans to rebrand as Numinus Intelligence to leverage AI in mental health clinics across the U.S. The transaction involves issuing approximately 204.7 million Numinus shares. The acquisition aims to enhance mental health treatment offerings through AI-enabled solutions and generate revenue and profitability.
  • MAPS (Multidisciplinary Association for Psychedelic Studies)coreStrategic or Co-development Partner · 12 July 2021Health Canada approved the compassionate access trial of MDMA-assisted therapy for PTSD and concurrent disorders in collaboration with MAPS. This partnership enables real-world data collection on a regulated model for MDMA-assisted therapy, leveraging Numinus' clinical trial site infrastructure.
  • Dr. Gabor Maté (Clinical Advisory Council)minorStrategic or Co-development Partner · 26 May 2020Dr. Gabor Maté, a recognized physician and bestselling author, joined Numinus as a member of the Clinical Advisory Council. He collaborates with the Numinus team in an advisory capacity and facilitates connections within the mental health community.
  • Health CanadacoreStrategic or Co-development PartnerHealth Canada has granted Numinus Bioscience licenses enabling research, extraction, and production of controlled substances including psilocybin, DMT, MDMA, mescaline, psilocin, LSD, and ketamine. Through the Special Access Program (SAP), physicians can request access to psilocybin and MDMA for patients with treatment-resistant conditions.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Numinus Wellness competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Numinus Wellness social profiles

Digital presence

Numinus Wellness financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Numinus Wellness leadership team

Management profile

Number of profiles

Profiles13 records

Numinus Wellness subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Numinus Wellness funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Numinus Wellness M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Numinus Wellness

What does Numinus Wellness do?

Numinus Wellness operates an integrated mental health company delivering psychedelic-assisted therapy clinical services through owned clinics in Canada (Vancouver, Montreal, Toronto), board-accredited practitioner training programs for psychedelic therapy certification, and clinical trial site operations (Cedar Clinical Research) supporting psychedelic medicine research. Supporting infrastructure includes Numinus Bioscience, a Health Canada licensed laboratory for psychedelic compound production and extraction covering psilocybin, DMT, MDMA, mescaline, psilocin, LSD, and ketamine.

Is Numinus Wellness a public or private company?

Numinus Wellness is a public company. It is classified as public and is currently operating.

When was Numinus Wellness founded?

Numinus Wellness was founded in 2020. It employs 51 to 100 people.

Where is Numinus Wellness based?

Numinus Wellness is headquartered in Vancouver, Canada, in the North America region.

How does Numinus Wellness make money?

Three revenue lines are on record. Clinical Services Revenue is the primary driver. The others are practitioner Training Programs and laboratory & Research Services.

Does Numinus Wellness have an API?

No public API is recorded for Numinus Wellness.

What industry is Numinus Wellness in?

Numinus Wellness's product category is Mental Health Services. Its primary akta.pro industry code is HLALAEAA, General Mental Health Therapy Platforms (Talk Therapy), with a secondary code of HSADAJAH, Meditation Apps, Digital Courses & Online Communities. Its NAICS code is 621420 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NewsfileNuminus Wellness Inc. Provides Corporate UpdateNuminus Wellness Inc. filed its Q3 fiscal 2026 interim financial reports, reporting revenue of $4.5 million and a cash position of $0.5 million. The company expects these filings to satisfy regulatory requirements to revoke its British Columbia cease trade order and is pursuing a Canadian Securities Exchange listing.Stock TitanNuminus Q3 Results: Revenue $4.5M, Reports FiledNuminus Wellness filed all quarterly interim financial reports for fiscal 2026, including Q3 revenue of $4.5 million. The filings satisfy regulatory requirements to revoke the British Columbia Securities Commission's cease trade order, with a CSE listing application pending.NewsfileNuminus Wellness Inc. Announces Fourth Quarter Fiscal 2025 Results and Provides Corporate UpdateNuminus Wellness Inc. reported fourth-quarter fiscal 2025 results for the three months ended August 31, 2025, with revenue of $2.3 million, up 29.0% from Q3, and gross profit of $1.4 million on a 61.2% margin. Practitioner Training revenue rose 387.6% to $1.0 million, while CCR revenue fell 13.2% to $1.4 million. The company holds $0.5 million in cash and a $2.7 million working capital deficiency.Stock TitanNuminus Wellness Q4 Results: Revenue Up 29%Numinus Wellness Inc. reported fourth-quarter fiscal 2025 results for the three months ended August 31, 2025, with revenue of $2.3 million, up 29.0% from $1.8 million in Q3 2025. Practitioner Training revenue rose 387.6% to $1.0 million, while CCR revenue fell 13.2% to $1.4 million. The company ended the quarter with $0.5 million in cash and a $2.7 million working capital deficiency.Ticker ReportHead to Head Survey: Numinus Wellness (OTCMKTS:NUMIF) and UnitedHealth Group (NYSE:UNH)MarketBeat published a head-to-head investment comparison between UnitedHealth Group and Numinus Wellness, evaluating them across ten factors including analyst ratings, valuation, earnings, and institutional ownership.Markets DailyContrasting Numinus Wellness (OTCMKTS:NUMIF) and UnitedHealth Group (NYSE:UNH)This article presents a comparative analysis of UnitedHealth Group and Numinus Wellness across multiple financial and investment metrics, concluding that UnitedHealth Group outperforms Numinus Wellness on all 10 factors examined, including revenue ($449.71 billion vs. N/A), earnings per share ($15.54 vs. N/A), and analyst ratings (2.89 vs. 0.00). UnitedHealth Group has a consensus target price of $455.92, indicating a potential upside of 9.91%, while Numinus Wellness lacks analyst coverage. The comparison highlights UnitedHealth Group's diversified healthcare operations across UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx segments versus Numinus Wellness's focus on psychedelic-assisted psychotherapy services.Stock TitanNuminus Wellness cites role after Trump orderNuminus Wellness Inc. acknowledged President Trump's Executive Order directing US federal agencies to accelerate research, access, and regulatory review for psychedelic-based treatments including psilocybin, ibogaine, MDMA, and LSD. The Order directs the FDA to prioritize Breakthrough Therapy designations, establishes new investigational access pathways, and commits $50 million in federal support for state psychedelic treatment programs. Numinus positions its clinical trial site operations through Cedar Clinical Research and its practitioner training division as directly aligned to support the accelerated commercialization timelines outlined in the Order.NewsfileNuminus Wellness Responds to Trump Executive Order on Psychedelic TherapiesNuminus Wellness acknowledged President Trump's executive order accelerating psychedelic therapy research and access. The company highlighted its clinical trial site operations and practitioner training as key to scaling care. It noted that operational and reimbursement infrastructure remains a bottleneck.Stock TitanNuminus Wellness TSX Delisting Takes Effect April 22The Toronto Stock Exchange (TSX) determined on March 19, 2026 to delist Numinus Wellness Inc.'s common shares, with the delisting effective April 22, 2026, following shareholder authorization approved at the company's annual general meeting in August 2025. The company is already subject to a cease trade order, so the delisting will not change the current non-tradable status of its securities in Canada. Numinus has filed an application to list on the Canadian Securities Exchange as part of its strategy to restore trading, though this can only take effect after the cease trade order is revoked.NewsfileNuminus Wellness Provides Update Regarding Listing StatusNuminus Wellness Inc. announced that the Toronto Stock Exchange (TSX) Continued Listing Committee met on March 19, 2026 and determined to delist the Company's common shares, effective April 22, 2026, despite the delisting not being requested by the Company. The delisting will not change the current trading status of its securities, which are not presently tradable in Canada due to an existing cease trade order. The Company has filed an application to list on the Canadian Securities Exchange, which can only take effect after the cease trade order is revoked and the Company meets CSE listing requirements.